BR9702557A - Composição farmacêutica para o tratamento de neoplasias malignas e deficiências imunossupressoras e seu método de produção - Google Patents

Composição farmacêutica para o tratamento de neoplasias malignas e deficiências imunossupressoras e seu método de produção

Info

Publication number
BR9702557A
BR9702557A BR9702557A BR9702557A BR9702557A BR 9702557 A BR9702557 A BR 9702557A BR 9702557 A BR9702557 A BR 9702557A BR 9702557 A BR9702557 A BR 9702557A BR 9702557 A BR9702557 A BR 9702557A
Authority
BR
Brazil
Prior art keywords
immunosuppressive
deficiencies
treatment
pharmaceutical composition
production method
Prior art date
Application number
BR9702557A
Other languages
English (en)
Other versions
BR9702557B1 (pt
Inventor
Paul Huber
Original Assignee
Paul Huber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Huber filed Critical Paul Huber
Priority to BRPI9702557-7A priority Critical patent/BR9702557B1/pt
Priority to DE1998622792 priority patent/DE69822792T2/de
Priority to AU79018/98A priority patent/AU727853B2/en
Priority to US09/202,126 priority patent/US6143753A/en
Priority to CNB988011271A priority patent/CN1160070C/zh
Priority to EP98929162A priority patent/EP0956015B1/en
Priority to PCT/BR1998/000045 priority patent/WO1999001125A1/en
Priority to ES98929162T priority patent/ES2218835T3/es
Publication of BR9702557A publication Critical patent/BR9702557A/pt
Publication of BR9702557B1 publication Critical patent/BR9702557B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI9702557-7A 1997-07-02 1997-07-02 composição farmacêutica para o tratamento de neoplasias malignas e processo para fabricação de uma composição farmacêutica para o tratamento de neoplasias malignas. BR9702557B1 (pt)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI9702557-7A BR9702557B1 (pt) 1997-07-02 1997-07-02 composição farmacêutica para o tratamento de neoplasias malignas e processo para fabricação de uma composição farmacêutica para o tratamento de neoplasias malignas.
DE1998622792 DE69822792T2 (de) 1997-07-02 1998-06-29 Pharmazeutische zusammensetzung enthaltend thymin und kynurenin oder tryptophan
AU79018/98A AU727853B2 (en) 1997-07-02 1998-06-29 A pharmaceutical composition containing kynurenine and thymine or tryptophan and thymine
US09/202,126 US6143753A (en) 1997-07-02 1998-06-29 Pharmaceutical composition for the treatment of malignant neoplasms and immunosuppressive deficiencies and its method of production
CNB988011271A CN1160070C (zh) 1997-07-02 1998-06-29 一种含有犬尿氨酸和胸腺嘧啶或色氨酸和胸腺嘧啶的药物组合物
EP98929162A EP0956015B1 (en) 1997-07-02 1998-06-29 Pharmaceutical composition containing thymine and kynurenine or tryptophan
PCT/BR1998/000045 WO1999001125A1 (en) 1997-07-02 1998-06-29 A pharmaceutical composition containing kynurenine and thymine or tryptophan and thymine
ES98929162T ES2218835T3 (es) 1997-07-02 1998-06-29 Composicion farmaceutica que contiene timina y quinurenina o triptofano.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI9702557-7A BR9702557B1 (pt) 1997-07-02 1997-07-02 composição farmacêutica para o tratamento de neoplasias malignas e processo para fabricação de uma composição farmacêutica para o tratamento de neoplasias malignas.

Publications (2)

Publication Number Publication Date
BR9702557A true BR9702557A (pt) 1999-03-09
BR9702557B1 BR9702557B1 (pt) 2009-05-05

Family

ID=4067132

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9702557-7A BR9702557B1 (pt) 1997-07-02 1997-07-02 composição farmacêutica para o tratamento de neoplasias malignas e processo para fabricação de uma composição farmacêutica para o tratamento de neoplasias malignas.

Country Status (8)

Country Link
US (1) US6143753A (pt)
EP (1) EP0956015B1 (pt)
CN (1) CN1160070C (pt)
AU (1) AU727853B2 (pt)
BR (1) BR9702557B1 (pt)
DE (1) DE69822792T2 (pt)
ES (1) ES2218835T3 (pt)
WO (1) WO1999001125A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113938A1 (pt) * 2019-12-09 2021-06-17 Cellavit Representação De Produtos Naturais Ltda Suplemento alimentar vitamínico-mineral

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL358677A1 (en) 2000-03-14 2004-08-09 James Hardie Research Pty Limited Fiber cement building materials with low density additives
CN1243615C (zh) 2001-03-02 2006-03-01 詹姆士·哈代国际金融公司 涂洒装置
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
US8209927B2 (en) 2007-12-20 2012-07-03 James Hardie Technology Limited Structural fiber cement building materials
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
EP3684410A1 (en) * 2017-09-19 2020-07-29 Institut Curie Agonist of aryl hydrocarbon receptor for use in cancer combination therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113938A1 (pt) * 2019-12-09 2021-06-17 Cellavit Representação De Produtos Naturais Ltda Suplemento alimentar vitamínico-mineral

Also Published As

Publication number Publication date
US6143753A (en) 2000-11-07
EP0956015B1 (en) 2004-03-31
CN1236315A (zh) 1999-11-24
BR9702557B1 (pt) 2009-05-05
EP0956015A1 (en) 1999-11-17
DE69822792T2 (de) 2005-01-13
ES2218835T3 (es) 2004-11-16
DE69822792D1 (de) 2004-05-06
WO1999001125A1 (en) 1999-01-14
CN1160070C (zh) 2004-08-04
AU727853B2 (en) 2001-01-04
AU7901898A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
PT977748E (pt) Derivados benzopirano substituidos para o tratamento de inflamacao
DE69727517D1 (de) Festelektrolytkondensator und dessen Herstellungsverfahren
IL197903A (en) A pharmacovigilance containing riavirus to treat cell culture disorders and its kit
BR9708312A (pt) Derivados de 4-amino-pirimidina medicamentos contendo esses compostos sua aplicação e processo para sua fabricação
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
DE69806831T2 (de) Dithiolan Derivate, deren Herstellung und deren Heileffekt
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
DE69825434D1 (de) Schirmgehäuse und dessen herstellungsverfahren
ATA71696A (de) Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
DE69620982T2 (de) Polyalkylensuccinimide und deren nachbehandelte Derivate
DE69903279D1 (de) Fumagillolderivate und deren herstellngsverfahren
DE69810956T2 (de) Doppelschichtkondensator und dessen herstellungsverfahren
BR9604950A (pt) Composição farmacêutica contendo n-clorofenil carbamatos n-clorofeniltiocarbamatos e derivados de n-fosfonoglicina para inibir o crescimento de cânceres e vírus em mamíferos
DE69942519D1 (de) Festelektrolytkondensator und dessen Hestellungsverfahren
DE59911659D1 (de) Magnetlager und dessen anwendung
BR9702557A (pt) Composição farmacêutica para o tratamento de neoplasias malignas e deficiências imunossupressoras e seu método de produção
FI973254A0 (fi) Menetelmä aminoetyylietanoliamiinin ja/tai hydroksietyylipiperatsiinin valmistamiseksi
PT1041985E (pt) Combinacao de compostos benzociclo-heptapiridina e farmacos antineoplasicos para tratar doencas proliferativas
BR8805359A (pt) Uso de derivados de fluoron e composicao para o contraste de neoplasmas malignos
DE69737335D1 (de) Festelektrolytkondensator und dessen Herstellungsverfahren
DE69325234D1 (de) Toner und dessen Herstellungsverfahren
DE69728938D1 (de) Peptidantagonisten der zellulären mitogenese und motogenese und deren therapeutische verwendung
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c
HUP9700661A3 (en) Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. C1 8: A61K 31/513; A61K 31/196; A61K 31/405; A61P 35/00

Ipc: A61K 31/505, A61K 45/05

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/07/2009, OBSERVADAS AS CONDICOES LEGAIS.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/505 (2006.01), A61K 31/405 (2006.0

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14.07.2019